Calendario›QNRX›QRX003

QRX003

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Ensayo de Quoin Pharmaceuticals Ltd. en Sindrome de Netherton.

Lo que ha anunciado la empresa

La empresa anunció que alcanzó su objetivo principal…positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome. For the first six participants to complete 12 weeks of treatment, the study met its primary endpoint with statistical significance. Summary of CL-QRX003-004 Interim Results in Netherton Syndrome · The primary endpoint of 1-grade improvement or greater for IGA on all of the treatment area met the pre…

En un 8-K del 28 ago 2026, en una frase que nombra «QRX003». El documento en la SEC.

Fase

Fase 2/3

Estado

Reclutando pacientes

Participantes

8

previstos

Centros

1

Fin del objetivo primario

dic 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en oct 2025.

Lo que ha cambiado

Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.

Qué mide

Proporcion de sujetos con reduccion de 1 punto en la IGA (hasta la semana 16)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe goal of this clinical trial (via an expanded access Treatment Protocol) is to learn if QRX003 (an investigational drug) applied topically to the skin (including up to the entire body \[except the scalp\]) works to treat the genetic disease Netherton syndrome. It will also learn about the safety of QRX003. The main questions the trial aims to answer are: 1. Does QRX003 impact the clinical presentation of NS in adults and minors by improving the clinical symptoms (diseased skin area, itch, and discomfort; based on clinical scoring, subject self-assessment, and other criteria)? 2. What medical problems do participants have when taking QRX003? 3. What percent of subjects will require rescue therapy? Participants will: Take drug QRX003 twice daily (applied topically to all affected areas of the body excluding the scalp) for 3 months, visit the clinic once every 4-6 weeks for checkups and tests, and to keep a dosing diary that records the times they applied the drug.

Más ensayos de QNRX

Todos los de QNRX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06953466), actualizada en ago 2026.